Pathogens without payback: when sharing isn’t caring

The current framework for pathogen sharing, primarily facilitated by the World Health Organization (WHO), reflects a significant gap in global governance. While the International Health Regulations (2005) mandate countries to report public health emergencies and share information, there is no corresponding binding international mechanism ensuring equitable access to the resulting medical countermeasures. This highlights the tension between global public goods (like genomic data) and private intellectual property rights (held by pharmaceutical companies developing vaccines). UPSC aspirants should connect this to the ongoing negotiations for a Pandemic Treaty at the WHO, which aims to establish a more equitable system for pathogen access and benefit-sharing (PABS). The debate centers on how to compel nations and corporations to reciprocate the sharing of raw biological data with affordable access to life-saving technologies.

The disparity discussed is fundamentally an economic issue rooted in the global intellectual property (IP) regime. The development of vaccines, therapeutics, and diagnostics (VTDs) requires significant investment, which is protected by IP rights under the TRIPS Agreement of the World Trade Organization. However, the initial biological material—often sourced from LMICs—is treated as a freely available resource. This creates an extractive economic model where the value addition (and profit) occurs in developed nations, while the source nations pay high prices for the final product. Candidates should analyze this through the lens of technological sovereignty and the need for technology transfer. The failure to waive IP rights during the COVID-19 pandemic, despite proposals by India and South Africa, exemplifies this structural inequality and the dominance of market forces over global health equity.

From a social perspective, the inequitable access to medical countermeasures exacerbates global health disparities and violates the right to health, which is recognized internationally and implicit in Article 21 of the Indian Constitution. When life-saving interventions are concentrated in wealthy nations, LMICs suffer disproportionately during outbreaks, leading to preventable morbidity and mortality. This inequity also breeds mistrust; if countries feel exploited when they share pathogen data, they may be less willing to cooperate in the future, hindering global disease surveillance. For UPSC Mains, discuss how this dynamic undermines global solidarity and the importance of building robust domestic manufacturing capabilities in LMICs to ensure health security and self-reliance, rather than depending on the benevolence of developed nations.